Advisory Board

 

The agenda is being shaped by an industry advisory board, with members including:

 

Uwe Gudat

Uwe Gudat 
Head of Safety, Biosimilars 
Merck

Alain Beck

Alain Beck 
Senior Director Analytical Chemistry, CIPF and Associate Editor 
mAbs 

Paul Chrisp

Paul Chrisp 
Programme Director, Medicines and Prescribing Center 
NICE

Gianluca Trifirò

Gianluca Trifirò 
Assistant Professor of Pharmacology 
Erasmus Medical Center

 

 Cecil Nick

Cecil Nick
Vice President, Biotechnology
PAREXEL

Steinar Madsen

Steinar Madsen
Medical Director, Department of Drug Information
Norwegian Medicines Agency

Ingrid Schwarzenberger

Ingrid Schwarzenberger
Head Global Regulatory Affair
Sandoz Biopharmaceuticals

adam levysohn

Adam Levysohn
Head of Global Market Access Biogen Biosimilars Business Unit
Biogen

 

Jonathan Underhill, Associate Director for Medicines Evidence, NICE

Jonathan Underhill 
Associate Director for Medicines Evidence 

NICE

Jatinder Harchowal, Chief Pharmacist / Clinical Director, Medicines Management & Clinical Support Services Business Unit Pharmacy Dept, The Royal Marsden NHS Foundation Trust

Jatinder Harchowal 
Chief Pharmacist / Clinical Director, Medicines Management & Clinical Support Services Business Unit Pharmacy Dept
The Royal Marsden NHS Foundation Trust

Philip Ball, Market Access Manager, NAPP Pharmaceuticals

Philip Ball 
Market Access Manager
NAPP Pharmaceuticals

Peter Jorgensen , CEO, Danish Generic and Biosimilar Medicines Industry Association (IGL)

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates